Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.63 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.59 |
| ▸ | CMA1 | P23946 | 8/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7148899 | 1.00 | ACE (0.63) | ACEKLK5CMA1F2PRSS1 | |
| SCHEMBL7538363 | 0.96 | ACE (0.59) | ACEKLK5CMA1F2PRSS1 | |
| SCHEMBL7272846 | 0.96 | ACE (0.59) | ACEKLK5CMA1F2PRSS1 | |
| SCHEMBL7539511 | 0.96 | ACE (0.59) | ACEKLK5CMA1F2PRSS1 | |
| SCHEMBL25448062 | 0.94 | ACE (0.57) | ACEKLK5CMA1F2PRSS1 | |
| SCHEMBL6435112 | 0.94 | ACE (0.57) | ACEKLK5CMA1F2PRSS1 | |
| SCHEMBL8366751 | 0.94 | ACE (0.56) | ACEKLK5CMA1F2PRSS1 | |
| SCHEMBL7321218 | 0.93 | ACE (0.60) | ACEKLK5CMA1F2PRSS1 | |
| SCHEMBL10403794 | 0.93 | ACE (0.56) | ACEKLK5CMA1F2PRSS1 | |
| SCHEMBL7268512 | 0.91 | KLK5 (0.69) | ACEKLK5CMA1F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877815-B2 | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-5494898-A | DIQUATERNARY TRIPEPTIDES | OHMEDA PHARMACEUTICAL PRODUCTS DIVISION INC. (US) | 1996-02-27 | — | — | US | disclosed |
| EP-0498941-A2 | Peptide skeletal muscle relaxants | BOC Health Care, Inc. (US) | 1992-08-19 | — | — | EP | disclosed |
| US-4971993-A | HYPOTENSIVE DIPEPTIDES DERIVATIVES | AJINOMOTO CO., INC. (JP) | 1990-11-20 | — | — | US | disclosed |
| EP-0190852-A2 | Dipeptide derivatives and antihypertensive drugs containing them | AJINOMOTO CO., INC. (JP) | 1986-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | MME, REN, ECE1 | ACE 7/4885KLK5 428/4885CMA1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.